SynthesisClinical pharmacology and therapeutics2019
Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink.
Synthesis in Clinical pharmacology and therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 61 citations in OpenAlex.
- Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial.Circulation. Genomic and precision medicine · 2022Trial
- Polygenic risk scores in pharmacogenomics: methodological challenges, current applications, and perspectives for clinical implementation.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2026Article
- Impact of Pharmacokinetic Gene Polymorphisms on Statin-Induced Myotoxicity in Thai Patients Treated With Simvastatin.Clinical and translational science · 2026Article
- Statin Use Is Associated With a Decline in Muscle Function and Mass Over Time, Irrespective of Statin Pharmacogenomic Score.Journal of cachexia, sarcopenia and muscle · 2025Article
- Retrospective Evaluation of the Impact ofJournal of personalized medicine · 2025Article
- Unveiling hidden risks: pharmacogenetic insights from a cross-sectional study of statin therapy in the Indian population.Pharmacological reports : PR · 2025Article
- Understanding the causes and consequences of low statin adherence: evidence from UK Biobank primary care data.BMC medicine · 2025Article
- SLCO1B1 Functional Variants, Bilirubin, Statin-Induced Myotoxicity, and Recent Sub-Saharan African Ancestry: A Precision Medicine Health Equity Study.Clinical pharmacology and therapeutics · 2025Article
- SLCO1B1 variants in a patient of African ancestry presenting with rosuvastatin-induced rhabdomyolysis: A case report.British journal of clinical pharmacology · 2025Article
- X chromosome dosage drives statin-induced dysglycemia and mitochondrial dysfunction.Nature communications · 2024Article
- Article
- Utilizing Pharmacogenomic Data for a Safer Use of Statins among the Emirati Population.Current vascular pharmacology · 2024Article
- Epidemiology of the idiopathic inflammatory myopathies.Nature reviews. Rheumatology · 2023Review
- PharmVar GeneFocus: SLCO1B1.Clinical pharmacology and therapeutics · 2023Review
- Cardiovascular precision medicine - A pharmacogenomic perspective.Cambridge prisms. Precision medicine · 2023Review
- Genetic VariantPharmaceutics · 2022Article
- The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.European heart journal. Cardiovascular pharmacotherapy · 2022Article
- Ethnic Diversity and Warfarin Pharmacogenomics.Frontiers in pharmacology · 2022Review
- Personalizing treatments for patients based on cardiovascular phenotyping.Expert review of precision medicine and drug development · 2022Article
- Effect of Green Tea Extract and Soy Isoflavones on the Pharmacokinetics of Rosuvastatin in Healthy Volunteers.Frontiers in nutrition · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 8 institutions in 5 countries.
Funding
Abstract
Statins can be associated with myopathy. We have undertaken a genomewide association study (GWAS) to discover and validate genetic risk factors for statin-induced myopathy in a "real-world" setting. One hundred thirty-five patients with statin myopathy recruited via the UK Clinical Practice Research Datalink were genotyped using the Illumina OmniExpress Exome version 1.0 Bead Chip and compared with the Wellcome Trust Case-Control Consortium (n = 2,501). Nominally statistically significant single nucleotide polymorphism (SNP) signals in the GWAS (P < 5 × 10
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.